SCHEMBL29649503

SCHEMBL29649503

COC(=O)c1ccc(NC(=O)[C@@H](N)CCCCNC(c2ccccc2)(c2ccccc2)c2ccc(C)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 4/20 0.44
LTA4H P09960 1/20 0.42
LNPEP Q9UIQ6 4/20 0.41
ERAP2 Q6P179 3/20 0.41
PTPN1 P18031 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
KIF11 P52732 3/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29649482 0.87 LTA4H (0.41) ALDH1A1MAPTLTA4HHTTMEN1
SCHEMBL29649451 0.86 SPHK1 (0.45) ALDH1A1LTA4HMAPK1KIF11
SCHEMBL31681497 0.86 SPHK1 (0.45) ALDH1A1LTA4HMAPK1KIF11
SCHEMBL29649513 0.86 KLKB1 (0.42) ALDH1A1L3MBTL1GAAMAPTPTPN1
SCHEMBL29649438 0.83 LTA4H (0.43) ALDH1A1LTA4HKIF11
SCHEMBL25208187 0.81 LTA4H (0.47) L3MBTL1LTA4HHTTRAB9ANPC1
SCHEMBL18388780 0.80 LTA4H (0.48) L3MBTL1LTA4HKMT2AKIF11
SCHEMBL25223009 0.80 LTA4H (0.48) L3MBTL1LTA4HKMT2AKIF11
SCHEMBL30148489 0.80 KIF11 (0.60) KIF11
SCHEMBL2238290 0.80 KIF11 (0.60) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4237008-A2 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF Elucida Oncology, Inc. (US) 2023-09-06 EP disclosed
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF ELUCIDA ONCOLOGY, INC. 2023-08-03 US disclosed
WO-2022093800-A2 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF ELUCIDA ONCOLOGY, INC. (US) 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230241243-A1 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF NDC1, KIFC1, SDCBP ALDH1A1 1060/4885L3MBTL1 1936/4885GAA 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.